KR101721685B1 - Composition for Removing dandruff, Preventing hair loss, and Promoting hair growth - Google Patents
Composition for Removing dandruff, Preventing hair loss, and Promoting hair growth Download PDFInfo
- Publication number
- KR101721685B1 KR101721685B1 KR1020150068969A KR20150068969A KR101721685B1 KR 101721685 B1 KR101721685 B1 KR 101721685B1 KR 1020150068969 A KR1020150068969 A KR 1020150068969A KR 20150068969 A KR20150068969 A KR 20150068969A KR 101721685 B1 KR101721685 B1 KR 101721685B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hair
- composition
- hair growth
- growth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 230000003779 hair growth Effects 0.000 title claims abstract description 43
- 208000001840 Dandruff Diseases 0.000 title claims abstract description 21
- 230000001737 promoting effect Effects 0.000 title claims abstract description 9
- 230000003658 preventing hair loss Effects 0.000 title abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 162
- 241001474374 Blennius Species 0.000 claims abstract description 25
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims abstract description 25
- 241000219823 Medicago Species 0.000 claims abstract description 23
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 21
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 21
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 20
- 201000004384 Alopecia Diseases 0.000 claims description 30
- 230000003676 hair loss Effects 0.000 claims description 22
- 208000024963 hair loss Diseases 0.000 claims description 20
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 16
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 16
- 235000021283 resveratrol Nutrition 0.000 claims description 16
- 229940016667 resveratrol Drugs 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 2
- 102000015833 Cystatin Human genes 0.000 abstract description 8
- 108050004038 cystatin Proteins 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 description 47
- 230000000694 effects Effects 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 230000006872 improvement Effects 0.000 description 28
- 239000000126 substance Substances 0.000 description 28
- 241000512259 Ascophyllum nodosum Species 0.000 description 19
- 210000004209 hair Anatomy 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 206010061218 Inflammation Diseases 0.000 description 18
- 230000004054 inflammatory process Effects 0.000 description 17
- 210000003780 hair follicle Anatomy 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229960003632 minoxidil Drugs 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 7
- 230000003803 hair density Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 6
- 230000003695 hair diameter Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000219094 Vitaceae Species 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940098366 cola extract Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 240000007124 Brassica oleracea Species 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 208000004631 alopecia areata Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 235000021021 grapes Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229940117382 propecia Drugs 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 241000555688 Malassezia furfur Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940069765 bean extract Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000036758 dandruff formation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012449 sabouraud dextrose agar Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- -1 sulfate polysaccharide Chemical class 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 235000015487 sulforaphane Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011303 Brassica alboglabra Nutrition 0.000 description 1
- 235000011302 Brassica oleracea Nutrition 0.000 description 1
- 235000001171 Brassica oleracea var gongylodes Nutrition 0.000 description 1
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 241000980780 Cladosiphon okamuranus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000220221 Rosales Species 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Natural products C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009646 cyclic growth Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003662 hair growth rate Effects 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001208 inner root sheath cell Anatomy 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000001297 telogen effluvium Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a composition for improving dandruff removal and hair loss prevention and for promoting hair growth, which comprises a cystatin tu tubulosa extract, a seaweed extract, a broccoli sprout extract, a variety extract, an alfalfa extract, a collavi extract, 0.2): 1 (占 0): 0.5 占 0.07: 0.1 占 0.03: 0.1 占 0.03: 0.1 占 0.03: 0.1 占 0.03.
Description
The present invention relates to a composition for prevention of hair loss and hair growth, and more particularly, to a composition for preventing hair loss and hair growth, and more particularly, to a composition for preventing hair loss and hair growth, which comprises dysentery removal including alopecia cisterna, kelp extract, broccoli sprout extract, various extract, alfalfa extract, And to a composition for promoting hair growth.
Recently, hair loss has increased not only in middle age but also in youth. Therefore, there is great interest in finding safe and easy materials that can prevent hair loss, promote regrowth of hair follicles, and promote hair growth. Currently, there are many studies on hair loss treatment, but there is no innovative development yet (Hwang, 2007). Thus, it has been scientifically proven that it is more effective to apply various combination therapies than to rely on one type of treatment.
Currently on the market are minoxidil (MXD), finasteride, propecia, and the like. Minoxidil has been developed as a vasodilator for the treatment of hypertension, but as a side effect, it has been developed as a hair growth agent (Burton and Marshall, 1979). Although the mechanism of action of the minoxidil on the hair growth effect has not been clarified to date, it is thought that the increase of nutritional supply through vasodilation and the tassium channel opening effect induce hair growth (Meisheri et al. , 1988; Buhl et al., 1990a, 1990b). These minoxidil are known to be effective against male-pattern baldness (androgenic alopecia) by male hormones in baldness therapy, but the treatment effect disappears within a few months after discontinuation of treatment. In contrast, finasteride and propecia are therapeutic agents for the treatment of benign prostatic hyperplasia and leukoplakia. Type II 5-reductase (type II 5), an enzyme that converts testosterone to dihydrotestosterone (DHT) -reductase) (Kaufman et al., 1999). This enzyme is present in the hair papilla cells of the hair follicle base, and finasteride and propecia are effective for male hair loss.
On the other hand, hair follicles are remodeled themselves through cycles of anagen, catagen, telogen, and exogen (Paus and Cotsarelis, 1993). During decline, hair follicles undergo programmed cell death, that is, apoptosis, which reduces size and enters the pauses (Cotsarelis, 1997). Hair follicles are regenerated at the beginning of the next growing season, requiring the activation of stem cells in the swollen hair follicles (Cotsarelis et al., 1990). Proliferating stem cells form new hair follicle matrix during the early growth period, and hair shaft and inner root sheath are derived from relatively undifferentiated basal cells (Oshima et al., 2001). The size and length of hair follicle stem are proportional to the size of hair follicle and the duration of growth period, respectively. The cyclic growth of these hair follicles is regulated by various growth factors.
On the other hand, the most common forms of hair loss include male pattern baldness or general baldness, telogen effluvium, cancer-induced hair loss, and alopecia areata. C57BL / 6 C3H / HeJ mice are used as model animals for hair loss studies. This C57BL / 6 mouse is characterized by black body hair and spontaneous alopecia. In the C57BL / 6 C3H / HeJ mouse, melanocytes are present only in the hair follicles, and the synthesis of melanin is in good agreement with the hair growth cycle to determine the hair growth cycle (Pals et al., 1989; Mller-Rver et al., 2001). This C3H / HeJ mouse has histologic and immunohistological characteristics similar to human alopecia areata (Sundberg et al., 1994). Female C3H / HeJ mice over 6 months of age develop alopecia areata with a frequency of 20%, with lymphocytes infiltrating around the hair follicle and effective in steroids, similar to the effect of human immunotherapy (Freyschmidt-Paul et al. , 1999).
As described above, various studies such as providing various causes for hair loss and developing a therapeutic agent or a functional composition for treatment have been actively conducted, but a solution for obtaining excellent effects has not been proposed.
It is an object of the present invention, which is devised to overcome the above-described problems, to provide a method for treating at least one of sea tangle extract, broccoli sprout extract, alfalfa extract, colbai extract, And to provide a composition for improving dandruff removal, hair loss prevention, and hair growth promotion that can prevent hair loss and promote hair growth.
In order to achieve the above object, the composition for improving dandruff removal and hair loss prevention and hair growth promotion according to the present invention is characterized in that the extract of the cystatin, the sea tangle, and the broccoli sprout are mixed in a ratio of 3 (± 0.2): 1 ): 0.5 (+/- 0.07) parts by weight.
In addition, it was also found that a composition obtained by further mixing at least one of 0.1 (± 0.03) parts by weight of various extracts, 0.1 (± 0.03) parts by weight of alfalfa extract 0.1 (± 0.03) parts by weight of collavi extract and 0.1 (± 0.03) parts by weight of resveratrol .
The extracts were mixed with 5.4 mg / kg of various extracts, 5.4 mg / kg of alfalfa extract, 5.4 mg / kg of collavi extract, , And 5.4 mg / kg of resveratrol.
INDUSTRIAL APPLICABILITY As described above, according to the present invention, the sea tangle extract and the broccoli sprout extract are mixed at a certain ratio to the hairless tobacco extract to promote hair growth.
In addition, by further mixing at least one of the various extracts, alfalfa extract, cola extract, and resveratrol, it is possible to maximize hair loss prevention and hair growth promotion by enhancing blood circulation improvement, providing hair nutrients, and dissolving thrombus .
In addition, the composition in which these components are mixed has an excellent effect on suppression of dandruff on the scalp and anti-inflammatory effect.
The composition of the present invention is not only in the form of a shampoo or a hair tonic, but also in a variety of functional foods such as tablets or beverages to prevent hair loss and activate hair growth.
BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate preferred embodiments of the invention and, together with the description, serve to further the understanding of the technical idea of the invention, It should not be interpreted.
The present invention relates to a composition for improving dandruff removal and hair loss prevention and a composition for promoting hair growth, which comprises a cystatin, a seaweed extract, a broccoli sprout extract, a variety of extracts, an alfalfa extract, a collavi extract, A graph showing the growth rate of hair growth for each test substance including the composition according to the ratio of single or mixture, the normal control group and the comparative substance group for 21 days.
Fig. 2 is a photograph showing the degree of hair growth by time of the experimental mouse on the 21st day in Fig.
FIG. 3 is a photograph showing the tissue change of the experimental mouse on
FIGS. 4A and 4B are graphs showing γ-GTP activity on the 14th day and 21st day in FIG.
FIG. 5 is a graph showing ALP activity measured after application or oral administration of the test substance of FIG. 1 to a mouse. FIG.
FIG. 6 is a graph showing the amount of EGF expression measured after application or oral administration of the test substance of FIG. 1 to a mouse. FIG.
FIG. 7 is a graph showing the amount of VEGF expression measured after application or oral administration of the test substance of FIG. 1 to a mouse. FIG.
FIG. 8 is a photograph showing the change of hair density after oral administration of the test substance of FIG. 1 orally after oral administration of the test substance to the normal hair loss patients.
FIG. 9 is a graph showing changes in hair density after 8 weeks and 16 weeks after oral administration of the test material of FIG.
FIG. 10 is a photograph showing changes in hair thickness after 16 weeks of oral administration of the test substance of FIG.
FIG. 11 is a graph showing changes in hair thickness after 8 weeks and 16 weeks after oral administration of the test material of FIG.
FIG. 12 is a graph showing the visual evaluation scores of dandruff and inflammation and hair loss improvement by the testees after 8 weeks and 16 weeks after the oral administration of the test material of FIG. 1 to the patients who had formalized hair loss.
FIG. 13 is a graph showing the subjective scores of dandruff and inflammation and alopecia improvement by the test subjects after 8 weeks and 16 weeks after the oral administration of the test material of FIG. 1 to the patients who had been prescribed formaldehyde.
FIG. 14 is a photograph showing the results of evaluating the anticancer activity inhibitory effect according to the sole or blending ratio of the cilostazol extract, seaweed extract, and
FIG. 15 is a graph showing the results of evaluating inhibitory effect of increased macrophage production of macrophages on RAW 264.7 cell culture system of the extracts of sea tangle, seaweed extract, and
FIG. 16 is a graph showing the results of inhibition of nitrogen concentration and inhibition of prostaglandin E 2 content in inflammation-inducing substances in air pockets, which are included in the composition according to the present invention. Fig.
FIG. 17 is a graph showing the results of inflammatory cell infiltration of infiltration of inflammatory cells into the cytochalasinus tuberosum extract, sea tangle extract, and
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. However, the detailed description of known functions and configurations incorporated herein will be omitted when it may unnecessarily obscure the subject matter of the present invention.
<Configuration>
The composition for improvement of dandruff removal and hair loss prevention and hair growth promotion according to the present invention comprises Cistanche tubulosa extract, kelp extract and broccoli sprout extract as main ingredients, and various extracts, alfalfa extract, cola extract Non-extract, resveratrol is used as auxiliary material. Each material and mixing ratio will be described in detail below.
First, the sheath tincture extract is mixed with 3 (± 0.2) parts by weight. Such a cystathanum tubuloosa extract is a powder form extracted from a cystathanum tubulosa by extraction with 80% ethanol, sterilization and drying. Here, it is distributed in the ovine grassland of the cystotypes, and it is called "desert ginseng" because it is thick and thick in meat quality, and its section is oily and glossy. It has also been reported that the cytotoxic agent TNF- and IL-4 production, which are the major cytokinases required for the isolation of nitric oxide (NO) from inflammatory cells, has been reported to be lowered, and also has a strong anti-inflammatory effect in animal experiments Yamada et al., 2010; Kyung et al., 2012). In addition, Sysanthus tetuberus exhibited an excellent effect on the improvement of blood circulation by lowering the blood cholesterol level, and the effectiveness of blood circulation promotion, vasodilation, hair growth, dandruff and inflammation improvement I could confirm.
In addition, sea tangle extract (including fucoidan) is mixed at 1 (± 0.1) parts by weight. This kelp extract was obtained by washing, drying and grinding kelp, hot water extraction at 60 ° C for one day, filtering with 0.45 μm membrane filtration, concentration, sterilization, spraying, drying and concentration. Recently, kelp extract has been reported to have excellent thrombolytic efficacy in the prevention and improvement of ischemic diseases (Min et al., 2012a, 2012b). This seaweed extract is a sulfate polysaccharide complex that can be obtained from seaweeds such as Laminaria japonica, Undaria pinnatifida Sporophyll and Cladosiphon okamuranus in many countries. . In previous studies, seaweed extracts reported antioxidant, anticoagulant, anticancer and anti-inflammatory effects (Feldman et al., 1999; Wang et al., 2010). Therefore, the usefulness of seaweed extracts for inflammatory diseases, ischemia, decreased immunity, and tumors has attracted the attention of researchers (Bojakowski et al., 2001; Li et al., 2005). This kelp extract was able to confirm the efficacy of the composition of the present invention for the maintenance and production of healthy hair by enhancing the immunity mechanism of the scalp and hair follicle through blood circulation improvement, anticoagulation and thrombolysis.
In addition, the broccoli bud extract is mixed with 0.5 (0.07) parts by weight. This broccoli sprout extract was obtained by washing, drying and pulverizing broccoli sprouts which are a popular vegetable rich in vitamin C, K, A and fiber, extracting with 70% ethanol at 40 ℃, sterilization, drying and concentrating. The broccoli sprout extract of the present invention contains sulforaphane as a main component. This sulforaphane is more abundant in buds than in broccoli adults (Fahey et al., 2002) and has anti-cancer and anticancer effects through induction of anti-cancer enzymes, apoptosis of cancer cells, inhibition of cell damage and angiogenesis inhibition In the present invention, the composition of the present invention has been reported to have an effect of enhancing and detoxifying the immune system (Fahey et al., 2002; Haristoy et al., 2003; Yanaka et al., 2009) Enhancement of ingredients, improvement of dandruff, dandruff and inflammation were confirmed in the experiments described below.
Then, the colorful extract is mixed with 0.1 (0.03) parts by weight. The various extracts were obtained by extracting, sterilizing, drying and concentrating the variety of green, yellow vegetables belonging to the cruciferous group with 70% ethanol. A variety of vitamins, vitamins or vitamins, and vitamin A is a precursor to the content of carotene is two times the amount of spinach, 100 g of dietary supplement contains 80% of the adult daily vitamins needed to help blood, blood It is known to have functionality to improve circulation. The various extracts obtained from these varieties were found to be effective in the hair health and hair growth through the hematopoietic action and the enhancement of blood circulation promotion in the composition of the present invention.
Further, the alfalfa extract is mixed with 0.1 (0.03) parts by weight. This alfalfa extract was obtained by extracting, sterilizing, drying and concentrating alfalfa, which is a perennial herbaceous plant belonging to the soybean family called alfalfa, in 70% ethanol. Alfalfa has a protein content of more than 25% and has a very good composition of other nutrients (nitrogen, phosphorus, potassium, calcium, boron, sulfur, molybdenum, magnesium, etc.). Recently, a kind of phytoestrogen Alfalfa, which contains a large amount of quercetin and coumesterol, has been increasingly used as a result of its lowering of cholesterol, the improvement of skin beauty and hypertension, and so on. The alfalfa extract obtained from these alfalfa was found to be effective in lowering cholesterol and blood pressure as well as enhancing nutritional content of hair and improving hair growth.
In addition, the cola extract is mixed with 0.1 (0.03) parts by weight. This cola bean extract is a two-year-old vegetable of the genus Papaveraceae, Brassica oleracea (Kohlarbi), which is extracted from 70% ethanol, which is also known as turnip cabbage or caliber cabbage, Lt; / RTI > Cobra is rich in anthocyanins, carotenoids, vitamin C and glucosinolates, which are known to have excellent anticancer effects. They are rich in vitamin C and potassium compared to ordinary vegetables such as cabbage It has been known that it is effective for dieting because it has abundant dietary fiber with low calorie content, and has antimutagenic effect, and has synergistic effect on anti-inflammation and hair growth. .
Then, resveratrol is mixed with 0.1 (0.03) parts by weight. This resveratrol is extracted from grapes. The grapes belong to Rhamnale and Vitaceae, and the fruit is used for reproduction or processed into beverage, wine, jam, grape seed oil, and the like. So far, grape-based studies have shown that they have cardiovascular disease, anti-cancer activity, and immunomodulating activity. Among the physiologically active substances exhibiting such efficacy, resveratrol is a representative substance, and phenolic acid, catechin, flavonoid, proanthocyanidin, and the like are present in various forms. When cultivating grapes, grape leaves are usually pruned, usually discarded. However, young grape leaves can be used not only for edible purposes but also for antioxidative and antiinflammatory effects, thus preventing and improving human diseases. Here, resveratrol was washed with fresh water immediately, and dried in a dryer at 60 to 70 ° C for a day. 100 g of grape leaves were extracted with 1,000 ml of 80% ethanol for one week, and then filtered and washed with a rotary vacuum concentrator And dried at -70 ° C in a freeze dryer (Eyela, FDU-2100, Tokyo Rikakikai Co., Tokyo, Japan). Such resveratrol is excellent in thrombolytic effect and is superior in safety and activity as a metabolite of edible plant compared to conventional thrombolytic agent and can be administered orally unlike conventional thrombolytic agents administered mainly through intravenous injection, , Pulmonary vascular diseases, and the like, and it has been confirmed that it is particularly effective in improving blood circulation and promoting hair growth.
<Experiment>
[Animal experiment]
According to the present invention, a mixture of 3: 1: 0.5: 0.1: 0.1: 0.1: 0.1: cysteine body extract, seaweed extract, broccoli sprout extract, various extracts, alfalfa extract, collavi extract and resveratrol The composition is made. Various test materials, including the composition of the present invention, were prepared for the experiment and the resultant contrast of the composition according to the present invention. As a test substance, a normal control group of saline, 3% of minoxidil, and 54 mg / kg of
1. Experimental animals
Experimental animals of the composition according to the present invention were male C57BL / 6 mice at 5 weeks of age and male ICR mice for investigation of hair growth from Orient Bio (Korea) (Horizontal) × 200 (vertical) × 145 (height) (mm) size mouse cage. The environment of the laboratory was adjusted to 23 ± 2 ℃, 55 ± 10% relative humidity, 12 times / hour of ventilation, 12 hours of illumination period, and illumination of 150 ~ 300 Lux. Purina Rat Chow, a pellet-type solid feed for laboratory animals, was supplied and received from Biopia (Korea, Inc.), and the drinking water was allowed to ingest sterile purified water freely.
At 6 weeks of age, the dorsal part of the mouse was removed with an electric razor to induce the dormant hair roots to grow (Hattori and Ogawa, 1983). In other words, if the pink hair was found to be pink after waiting for the epilating skin to uniformly pink, the remaining hair was shaved lightly so that it would not scratch the skin with a razor (Lee et al., 2006; Kim et al., 2009).
2. Test substance
2-1. Normal control group
On the next day of shaving, saline was applied to the shaved area 1-2 times a day for 21 days. The result of the hair growth is shown in Fig.
2-2. Comparative material group
On the next day after shaving, 3% of minoxidil was applied to the depilated skin with a brush about one time per day for about 21 days for 21 days. The result of the hair growth is shown in Fig.
2-3. Systannic
54 mg / kg of Sutentanum tubulosa extract was orally administered once a day for 21 days. The result of the hair growth is shown in Fig.
2-4.
18 mg / kg of kelp extract was orally administered once a day for 21 days. The result of the hair growth is shown in Fig.
2-5.
162 mg / kg of Sutentanus tubulosa extract was orally administered once a day for 21 days. The result of the hair growth is shown in Fig.
2-6.
54 mg / kg of kelp extract was orally administered once a day for 21 days. The result of the hair growth is shown in Fig.
2-7.
Kg of extracts of broccoli sprouts, 1.8 mg / kg of various extracts, 1.8 mg / kg of alfalfa extract, 1.8 mg / kg of collavi extract, 1.8 mg / kg of extracts of resveratrol Was orally administered once a day for 21 days. The result of the hair growth is shown in Fig.
2-8.
Kg of alfalfa extract, 5.4 mg / kg of collagen extract, 5.4 mg / kg of resveratrol, 5.4 mg / kg of alfalfa extract, Was orally administered once a day for 21 days. The result of the hair growth is shown in Fig. Here, the capacity of each of the ingredients in
3. Analysis of hair growth by age
The back region of the experimental animals was photographed before the administration of the test substance (0 day) and every 3 days after the administration to determine the hair growth effect. At this time, as a camera, a computerized image analysis system (Imageinside (company name), Korea) was used, and the hair growth rate of a regrowth area / shaved area per skin area Respectively.
3-1. Analysis of hair growth by time
Compared with the normal control group, the comparative substance group showed rapid hair growth promoting effect. In detail, on the 21st day, excellent hair growth effect was promoted by 92.4% of 29.2% of the normal control group (see FIGS. 1, 2A and 2B) ).
In addition,
Similar to
The
4. Histological examination
On the 14th and 21st days after the start of the test, the hairy areas and the skin of the delayed areas were removed and fixed with 10% formalin solution. The tissue was embedded in paraffin, and 5 tissue sections were prepared. Hematoxylin-eosin staining was performed to observe the number and histological changes of the hair follicles by optical microscope.
4-1. Histological examination results
The fidelity of the hair follicle was remarkably improved in the skin histopathological findings on the 14th day and 21st day of the comparative substance group compared to the normal control group (see FIG. 3A) (see FIG. 3B).
The fidelity of these hair roots was lower than that of the comparative substance group, but it was also improved in the
In particular, it was confirmed that the
5. Measurement of GTP (Glutamyl Transpeptidase) and ALP (Alkaline Phosphatase) Activity
The extracted skin tissue was immediately frozen in liquid nitrogen, and then 4 times a phosphate buffer (pH 7.4) was added and homogenized. The homogenate was centrifuged at approximately 3,000 rpm for approximately 20 minutes and the supernatant was used for GTP and ALP activity measurements. GTP and ALP activities were measured by enzyme rate assay (GSCC) using PNPP-DEAV ( P- nitrophenolphosphate) (Handiiski et al., 1994; Kim et al., 2009).
5-1. Results of GTP and ALP activity measurements
The GTP activity, which is known to induce hair roots to grow in the growth medium, was increased by 90 ~ 120% as compared with that of the normal control group as in the case of 14 days (FIG. 4A) and 21 days (FIG. 4B). In the case of
Also, ALP activity, which is known as an animal skeletal growth and angiogenesis index, showed a significant increase in both the 14th day (FIG. 5A) and the 21th day (FIG. 5B) in comparison with the normal control group. In addition,
6. EGF (Epidemal Growth Factor) and VEGF (Vascular Endothelial Growth Factor) expression level measurement
EGF and VEGF were measured using an enzyme-linked immunosorbent assay (ELISA) kit (R & D System, Minneapolis, USA) (Cross et al., 2003; Kim et al., 2009). That is, the production of two growth factors was quantitated by sandwich enzyme immunoassay using mouse EGF and VEGF specific polyclonal antibodies according to the manufacturer's guide.
6-1. Results of measurement of EFG and VEGF expression levels
Analysis of EFG promoting growth of hair follicles revealed that compared to the normal control group, the comparative substance group increased 3.5 times over both 14 days (Fig. 6A) and 21 days (Fig. 6B). In addition,
On the other hand, when the angiogenic factor VEGF was analyzed, compared with the normal control group, the comparative substance group increased about 80% at 14 days (Fig. 7A) and about 50% at 21 days (Fig. 7B). In addition,
7. Statistical processing
All measurements were expressed as mean standard error. When significance was observed after one-way analysis of variance (ANOVA), the significance between the test substances was tested at the level of P <0.05 through Turkey`s test.
[Clinical Experiment]
1. Test substance
(Hereinafter referred to as "MK"), which is prepared at a ratio of 3: 1: 0.5: 0.1: 0.1: 0.1: 0.1, is added to the extracts of Siltanthus truffilia, Seaweed extract, Broccoli sprout extract, -R7 or HGF-R7), a capsule containing 260 mg of the control maltodextrin was provided to the experimental group to compare the experimental results according to the dose. The control group was given two daily doses of Sisotanthus tuberosum extract, seaweed extract, broccoli sprout extract, colorful extract, alfalfa extract, cola extract, and placebo capsules containing no resveratrol. This is summarized in [Table 1] below.
2. Density and diameter of hair (thickness)
Clinical investigators affected by hair loss were shaved 2 mm in length with a 1 cm diameter circular shape near the crown. The density and diameter of the patient's hair were measured before the use of MK-R7 and 16 weeks after the phototrichogram (non-invasive imaging device (Folloscope) 4.0, Lead M) Were used for the measurement. The density of the hair was measured by counting the number of hairs in the 1 cm 2 area, and the diameter of the hair was measured by calculating the average value of the measured hair diameters.
2-1. Change in hair density (unit n / cm 2 ) Results (primary efficacy endpoint)
The mean of the hair density of the test group was 159.56 ± 28.34 (see FIG. 8A) before consumption of MK-R7 and 182.84 ± 32.96 (see FIG. 8B) after 16 weeks of consumption. The average of the hair mean densities of the control group is 150.18 ± 39.57 (see FIG. 8C) before consumption and 160.53 ± 37.55 (see FIG. 8D) after 16 weeks of consumption. All patients who participated in clinical trials experienced increased hair density. Here, the degree of change of hair density after 16 weeks was increased by 10.35 ± 20.08 in the control group and by 23.29 ± 24.26 in the test group, which is higher in the test group than in the control group. Thus, it can be seen that the increase in the hair density of the test group was statistically significant with the control group and fertilizer (see FIG. 9).
2-2. Results of variation of hair diameter (thickness, unit mm) (secondary efficacy evaluation variable)
The average hair diameter of the test group was 0.063 + 0.014 before consumption of MK-R7 (see FIG. 10A) and 0.086 + 0.018 (FIG. 10B) after 16 weeks. The control group was 0.071 ± 0.018 before consumption of MK-R7 (see Figure 10C) and 0.077 ± 0.015 after 16 weeks (see Figure 10D). Both control and test groups showed increased hair diameter. Both groups showed an increase in hair diameter. However, after 16 weeks, the test group showed a statistically significant increase in hair diameter as compared to the control group (see FIG. 11).
3. Researcher's Score and Subject's Subjective Score
At 8 weeks and 16 weeks, the researchers were provided with photographs of the head side of the test subjects at the top of the standard to check for improvement of hair loss symptoms and dandruff and scalp inflammation. The expert judged the degree of improvement on the 5-point scale (-1: worse, 0: no improvement, +1: fine improvement, +2: improvement, +3: remarkable improvement). In addition, questions were asked at 8 and 16 weeks to identify subjective improvement effects of test subjects on alopecia symptoms and improvement of dandruff and scalp inflammation, and subjects were assessed for improvement on a 5-point scale (-1: dissatisfied , 0: indifference, +1: somewhat satisfied, +2: satisfied, +3: very satisfied).
3-1. The researcher's visual assessment of dandruff, inflammation and hair loss improvement
Assessment by blinded surveys giving visual scores of clinical improvement of hair loss showed improvement in the mean scores of the two groups, with the test group receiving 0.52 ± 0.66 after 8 weeks and the control group receiving 0.24 ± 0.63. Also, after 16 weeks, the test group received 0.64 ± 0.78 and the control group received 0.51 ± 0.82, indicating an increase in the score, but the statistical difference between the two groups was not significant (see FIG. 12A). After 16 weeks, the scores of the researchers in each group showed a statistically significant difference in the scores given in the test and control groups. In addition, after 8 weeks, the test group received a mean score of 0.48 ± 0.62 and the control group received 0.30 ± 0.60 for visual improvement of the improvement effect of dandruff and inflammation. There was no significant statistical difference between the two groups, although there was a slight improvement in both groups. After 16 weeks, the test group received an average score of 0.68 ± 0.64, the control group received 0.35 ± 0.62, and the test group and control group showed significant differences (see FIG. 12B).
3-2. Patient's subjective alopecia improvement satisfaction score
The subjective rating of subjective hair loss improvement satisfaction was 2.55 ± 1.02 in the test group and 2.41 ± 1.04 in the control group after 8 weeks and 2.82 ± 1.01 in the test group and 2.49 ± 1.06 in the control group after 16 weeks , Proving that most participants are satisfied or very satisfied. However, there was no statistically significant difference between the two groups (see FIG. 13A). Regarding subjects' satisfaction with improvement of scalp dandruff and inflammation, the mean score of the test group was 2.21 ± 1.02 and the mean score of the control group was 2.02 ± 1.07 after 8 weeks. In addition, after 16 weeks, the mean score of the test group was 2.65 ± 1.04 and the mean score of the control group was 2.13 ± 1.05. The mean scores given to the test group and the control group thus showed a statistically significant difference (see FIG. 13B).
[Dandruff and inflammation related]
As an immune response to external antigens, macrophages have been implicated in inflammatory responses such as tumor necrosis factor-alpha, TNF-alpha, interleukin-1 beta, IL-1 beta and
Tumor necrosis factor receptors are important factors in inducing nitric oxide synthase (iNOS) genes in some cells. Activation of nitric oxide synthase promotes the production of nitrogen (NO), which causes inflammation, as well as dilating blood vessels, killing bacteria. On the other hand, the tissue damage causes the production of arachidonic acid by phospholipases in cell membrane phospholipids. This arachidonic acid is activated by cyclooxygenase (COXs) prostaglandins, PGs). Coke produced in -Ⅱ (cox-Ⅱ) excessive prostaglandin E 2 (prostaglandin E 2) by activation induces talkie ness between various proinflammatory. Nitric oxide (TNF-α-NO) and Cox-II-prostaglandin E2 (COX-Ⅱ-PGE2) pathways are the major pathogenetic pathways of NGF and NGF as nitric oxide and prostaglandin E 2 are important factors in inflammation and pain induction. These two pathways are inhibited by corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), respectively. Although there are a variety of steroid drugs and NSAIDs for the treatment of inflammatory diseases, these drugs have side effects in the immune system, gastrointestinal tract, kidney, liver, central nervous system, blood pressure, and cardiovascular system. Therefore, there is a need to minimize these side effects by replacing these chemical agents or by administering them in combination with natural products.
1. Dustpanic culture and killing efficacy
For the experiment of the composition according to the present invention, M. furfur ATCC 15421 was cultivated in Sabouraud dextrose agar (SDA) after being distributed from American Type Cluture Collection (ATCC; Manassas, USA). As an agar-dilution assay, each test substance was continuously diluted from 2 mg / mL to 0.004 mg / mL in a Sabouraud medium to prepare a medium. The cells were plated on paraffin oil and inoculated at 30 μL in accordance with 1.5 × 10 8 cells (MacFaland Nl. 0.5). After culturing for 72 hours, the colonies were observed to determine whether the cells were grown Respectively.
2. Cell culture and determination of nitrogen
RAW 264.7 macrophages were purchased from ATCC and contained 10% fetal bovine serum (Sigma, St. Louis, USA) and 100 U / mL of antibiotics (Sigma) And cultured in Dulbecco's modified Eagle's medium (DMEN; Sigma) in a humidified 5% CO 2 incubator at 37 ° C. In order to evaluate the effect of kelp extract and cis-tootrobula extract on nitrogen (NO) production, RAW 264.7 cells (1 × 10 6 cells / mL) were treated with 1-320 μL / mL of the test substance for 5 minutes 10 U / mL of interferon-y (interferon-y, IFN-y) and 10 μg / mL of lipopolysaccharide (LPS) were added and cultured for 24 hours. It was measured using the nitrite (nitrite, NO 2) oxidation reaction of nitrogen as an index of the nitrogen, the grease reagent (griess reagent) the same amount of culture solution of 1% sulfanyl amide (sulfanilamide), 0.1% in 2.5% phosphoric acid (phosphoric acid) The mixture was mixed with naphthylethylenediamide and allowed to react at room temperature for 10 minutes. Nitrogen content was measured at 540 nm and quantified using a standard quantitative curve of sodium nitrite (NaNo 2 ).
3. Experimental animals
Seven week old male ICR mice were received from Korea BioLink (company name, voice, Korea) and used for about 1 week after purification process. Animals were housed in cages (220 x 200 x 145 mm), four in each. The environment of the animal laboratory was controlled at a temperature of 23 ± 2 ° C, a relative humidity of 55 ± 10%, a ventilation frequency of 12 times / hour, a lighting cycle of 12 hours, and an illumination of 150-300 Lux. Purine Rat Chow, a pellet type solid feed for laboratory animals, was supplied and received from Biopia (company name, Gunpo, Korea), and the drinking water was allowed to drink sterilized purified water freely.
4. Administration of test substance and induction of inflammation
(18mg / kg) or sea tangle extract (54mg / kg), Sisotanthus bulurosa extract 1 (54mg / kg) or Sisotecum tubulosa extract 2 (162mg / kg) kg), mixture 1 (18 + 54 mg / kg) or mixture 2 (54 + 162 mg / kg) of a mixture of sea tangle extract and cystathanum tubulosa extract and
5. Exudative analysis
After 6 hours of injection of carrageenan, the bladder was rinsed with 1 mL of cold saline and the net volume of the lavage fluid was recorded. The number of inflammatory cells such as neutrophils, mononuclear leukocytes, and lymphocytes was measured with a coulter counter. The inflammatory mediators nitrogen and prostaglandin E 2 were measured by enzyme immunoassay (EIA) using a grease reagent (Sigma) and a correlate-EIA kit (Assay Eesigns, Ann Arbor, Ann ArboUSA).
6. Histopathological examination
The skin and subcutaneous tissues including the inner tissue of the bladder were collected and fixed with 10% neutral formalin solution. The tissues were embedded in paraffin, slides were prepared, stained with hematoxyling-eosin, and inflammatory findings were observed under an optical microscope.
7. Statistical processing
All measurements were expressed as mean ± standard error. When significance was observed after one-way analysis of variance (ANOVA), the significance between groups was tested at the level of P <0.05 through Turkey`s test.
8. Results
As a result of evaluating the inhibitory effect of Staphylococcus aureus extracts 1, 2,
In addition, the
As a result of measurement of the nitrogen content in the air bladder for the
As a result of evaluating the inhibitory effect on the inflammatory cell infiltration of the
In conclusion, the antimicrobial efficacy against M. furfur, which is a representative dandruff strain, was evaluated in order to examine the effect of anti-inflammatory effect on skin damage and itching by dandruff formation. , And
It will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. It is therefore to be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention is defined by the appended claims, rather than the detailed description, and all changes or modifications derived from the meaning and scope of the claims and equivalents of the claims are to be construed as being included within the scope of the present invention do.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150068969A KR101721685B1 (en) | 2015-05-18 | 2015-05-18 | Composition for Removing dandruff, Preventing hair loss, and Promoting hair growth |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150068969A KR101721685B1 (en) | 2015-05-18 | 2015-05-18 | Composition for Removing dandruff, Preventing hair loss, and Promoting hair growth |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160135532A KR20160135532A (en) | 2016-11-28 |
KR101721685B1 true KR101721685B1 (en) | 2017-03-30 |
Family
ID=57706835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150068969A KR101721685B1 (en) | 2015-05-18 | 2015-05-18 | Composition for Removing dandruff, Preventing hair loss, and Promoting hair growth |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101721685B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190005426A (en) | 2017-07-06 | 2019-01-16 | 농업회사법인(주)힐리안 | Composition for improving hair and scalp comprising nitric oxide-containing water and herbal extracts and manufacturing method thereof |
KR102033372B1 (en) | 2018-12-20 | 2019-11-29 | 김광남 | Functional soap composition with seaweed ear extract and process for preparing the same |
KR102195880B1 (en) | 2020-09-01 | 2020-12-29 | 주식회사 한미양행 | Composition for hair loss prevention or hair growth promotion containing cricket and Tenebrio molitor treated with high-pressure by steaming process and enzyme-decomposed |
WO2022075731A1 (en) * | 2020-10-07 | 2022-04-14 | 주식회사 아스트로제네시스 | Composition for promoting hair growth and/or inhibiting hair loss |
KR102523606B1 (en) | 2022-08-09 | 2023-04-19 | 주식회사 두래 | Cosmetic composition containing polysaccharide extracted from alfalfa seeds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070086972A1 (en) * | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI255192B (en) | 1999-11-30 | 2006-05-21 | Takara Bio Inc | The active composition for promoting hair growth and the cosmetic composition except for promoting hair growth |
JP2009203199A (en) | 2008-02-28 | 2009-09-10 | Oriza Yuka Kk | Hair-growing composition |
KR101383217B1 (en) * | 2011-09-16 | 2014-04-10 | (주)미스바알텍 | Composition for preventing hair loss and promoting hair growth |
-
2015
- 2015-05-18 KR KR1020150068969A patent/KR101721685B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070086972A1 (en) * | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190005426A (en) | 2017-07-06 | 2019-01-16 | 농업회사법인(주)힐리안 | Composition for improving hair and scalp comprising nitric oxide-containing water and herbal extracts and manufacturing method thereof |
KR102033372B1 (en) | 2018-12-20 | 2019-11-29 | 김광남 | Functional soap composition with seaweed ear extract and process for preparing the same |
KR102195880B1 (en) | 2020-09-01 | 2020-12-29 | 주식회사 한미양행 | Composition for hair loss prevention or hair growth promotion containing cricket and Tenebrio molitor treated with high-pressure by steaming process and enzyme-decomposed |
WO2022075731A1 (en) * | 2020-10-07 | 2022-04-14 | 주식회사 아스트로제네시스 | Composition for promoting hair growth and/or inhibiting hair loss |
KR102523606B1 (en) | 2022-08-09 | 2023-04-19 | 주식회사 두래 | Cosmetic composition containing polysaccharide extracted from alfalfa seeds |
Also Published As
Publication number | Publication date |
---|---|
KR20160135532A (en) | 2016-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101721685B1 (en) | Composition for Removing dandruff, Preventing hair loss, and Promoting hair growth | |
KR100794447B1 (en) | Hair growth stimulants and the method thereof | |
US8518462B2 (en) | Compound comprising extracts or fractions of chrysanthemum boreale makino having anti-inflammation activity | |
KR101851972B1 (en) | Mixed composition to prevent hair loss and promote growing hair providing natural oriental material including artemisiae apiaceae herba, chrysanthemi zawadskii herba, artemisiae argyi herba, artemisiae capillaris herba, sophorae fructus, cirsii herba, and aucklandiae radix extracts and manufacturing method using the same | |
KR102153414B1 (en) | Composition for improving hair loss and promoting hair growth containing a fermented soybean | |
KR101698922B1 (en) | Composition for promoting hair growth and restoration | |
KR100970126B1 (en) | Method of preparing?compositions for preventing depilation and for promoting hair-growing | |
KR20160008055A (en) | Composition for improving hair or skin conditions comprising Camellia japonica leaf extract | |
KR20140020005A (en) | Cistanche tubulosa, fucoidan extract for promoting hair growth and preventing hair loss & manufacturing method thereof | |
KR100773457B1 (en) | Composition promoting hair growth and use thereof | |
KR101517836B1 (en) | A composition for the treatment of atherosclerosis comprising the red ginseng complex | |
KR102612017B1 (en) | Composition for skin improvement comprising multiple extract | |
KR20180094820A (en) | Composition for prevention of losing hair or promotion of growing hair comprising bean extract | |
KR102611916B1 (en) | Composition for skin improvement comprising multiple extract | |
KR101833776B1 (en) | Composition for Preventing Alopecia and Improving Hair Growth Comprising the Extract of Anemarrhena Asphodeloides and Aralia Elata | |
KR101698869B1 (en) | A composition for treatment of Atopic dermatitis containing oriental medicine herbs | |
KR100991309B1 (en) | Chinese Composition for Hair Protection and Hair Growth-Promotion and Methods for Preparing the Same | |
CN116096389A (en) | RALDH2 expression enhancer | |
KR20110095765A (en) | Anti-allergic composition containing scrophularia buergeriana extract | |
KR101769123B1 (en) | Cosmetic composition containing natural complex extract for improving atopic dermatitis | |
KR102650115B1 (en) | Composition for improving hair loss and promoting hair growth containing Boehmeria spicata | |
KR102467403B1 (en) | Composition for preventing hair loss and promoting hair growth and method for manufacturing thereof | |
KR20190021614A (en) | Composition for antioxidant, antiinflammatory and inflammatory neurodegenerative diseases comprising perilla frutescens britton extract | |
KR102572769B1 (en) | A cosmetic composition for scalp care damaged by external stimuli or for alleviating stress-related hair loss containing a complex extract of buckwheat sprouts and chamomile pretreated with ultra-high pressure | |
KR102206870B1 (en) | Combined Formulation for Prevention or Treatment of Atopic Dermatitis and Process for Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |